Now Takeda Offers Rebate if Lung Cancer Drug Fails to Work Now Takeda Offers Rebate if Lung Cancer Drug Fails to Work
Following Pfizer ' s action with crizotinib, now Takeda is offering a rebate for brigatinib if it doesn ' t work. Both drugs are for ALK+ve non-small cell lung cancer.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Hematology | Lung Cancer | Non-Small Cell Lung Cancer | Pfizer